Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.
Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection.
复制标题
血管紧张素转换酶抑制剂对 HIV 和丙型肝炎合并感染肝纤维化的影响。
DOI:
10.1155/2012/978790
复制
发表时间:
2012
影响因子:
1.7
通讯作者:
Fishbein,DawnA
中科院分区:
文献类型:
--
作者:
Reese,LindseyJ;Tider,DianeS;Stivala,AliciaC;Fishbein,DawnA
Background. Liver fibrosis is accelerated in HIV and hepatitis C coinfection, mediated by profibrotic effects of angiotensin. The objective of this study was to determine if angiotensin converting enzyme inhibitors (ACE‐Is) attenuate liver fibrosis in coinfection.Methods. A retrospective review of 156 coinfected subjects was conducted to analyze the association between exposure to ACE‐Is and liver fibrosis. Noninvasive indices of liver fibrosis (APRI, FIB‐4, Forns indices) were compared between subjects who had taken ACE‐Is and controls who had not taken them. Linear regression was used to evaluate ACE‐I use as an independent predictor of fibrosis.Results. Subjects taking ACE‐Is for three years were no different than controls on the APRI and the FIB‐4 but had significantly higher scores than controls on the Forns index, indicating more advanced fibrosis. The use of ACE‐Is for three years remained independently associated with an elevated Forns score when adjusted for age, race, and HIV viral load (P< 0.001). There were significant associations between all of the indices and significant fibrosis, as determined clinically and radiologically.Conclusions. There was not a protective association between angiotensin inhibition and liver fibrosis in coinfection. These noninvasive indices may be useful for ruling out significant fibrosis in coinfection.